Blog

Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations

Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…

Certara2026 年 3 月 24 日

Blog Knowledge Base

What is GLP (good laboratory practice)?

Read this blog to understand GLP (Good Laboratory Practice) and associated QA audits, and proper…

Kevin Snyder, PhD2026 年 3 月 18 日

Blog

通过模型引导的药物开发促进药物公平：ASCPT 2026 见解

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

Certara2026 年 3 月 11 日

Blog

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

Certara2026 年 3 月 3 日

On-Demand Webinar

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…

Certara2026 年 2 月 23 日

Blog

FAQs: The ICH M15 guideline and what it means for model-informed drug development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

Certara2026 年 2 月 18 日

Blog

How model-informed drug development (MIDD) strengthens drug asset valuation and answers the questions investors care about most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

Certara2026 年 1 月 26 日

On-Demand Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…

Certara2026 年 1 月 22 日

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Certara2026 年 1 月 14 日

On-Demand Webinar

安全第一：揭示化合物筛选数据中的临床风险

Learn how to interpret screening assay data to predict clinical off-target risk with ToxStudio® and…

Certara2026 年 1 月 13 日

药物安全

Regulatory horizons 2026: Clinical pharmacology strategy and regulatory expectations

What is GLP (good laboratory practice)?

通过模型引导的药物开发促进药物公平：ASCPT 2026 见解

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

FAQs: The ICH M15 guideline and what it means for model-informed drug development

How model-informed drug development (MIDD) strengthens drug asset valuation and answers the questions investors care about most

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

安全第一：揭示化合物筛选数据中的临床风险

订阅时事通讯

快捷链接

解决方案

联系我们